We have shown that the IL-1βR antagonist SER140 at 10 mg/kg subcutaneously is able to prevent the destruction or damaging of the insulin producing β-cells and hence reduce the incidence of diabetes in female NOD mice. Here, INS is linked to diabetes mellitus.